Brokerages Expect Agile Therapeutics Inc (NASDAQ:AGRX) to Announce -$0.08 Earnings Per Share

Share on StockTwits

Analysts forecast that Agile Therapeutics Inc (NASDAQ:AGRX) will report earnings per share of ($0.08) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Agile Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.07). Agile Therapeutics posted earnings of ($0.11) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 27.3%. The firm is scheduled to report its next earnings report on Thursday, November 7th.

According to Zacks, analysts expect that Agile Therapeutics will report full year earnings of ($0.37) per share for the current fiscal year, with EPS estimates ranging from ($0.39) to ($0.34). For the next financial year, analysts expect that the business will report earnings of ($0.35) per share, with EPS estimates ranging from ($0.77) to $0.11. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Agile Therapeutics.

Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03.

Several research firms have commented on AGRX. Zacks Investment Research raised Agile Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 price target for the company in a report on Tuesday, August 6th. Oppenheimer began coverage on Agile Therapeutics in a report on Thursday, June 6th. They issued an “outperform” rating and a $5.00 price target for the company. Maxim Group set a $3.00 target price on Agile Therapeutics and gave the stock a “buy” rating in a report on Monday, June 10th. Finally, ValuEngine cut Agile Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Agile Therapeutics has an average rating of “Buy” and an average price target of $3.45.

Several institutional investors and hedge funds have recently modified their holdings of AGRX. Vanguard Group Inc. raised its holdings in shares of Agile Therapeutics by 129.8% in the 2nd quarter. Vanguard Group Inc. now owns 1,732,648 shares of the specialty pharmaceutical company’s stock worth $2,530,000 after buying an additional 978,672 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Agile Therapeutics by 5.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,254,180 shares of the specialty pharmaceutical company’s stock worth $3,291,000 after buying an additional 120,403 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Agile Therapeutics by 33.3% in the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 104,222 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Agile Therapeutics by 2,219.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 76,538 shares of the specialty pharmaceutical company’s stock worth $108,000 after buying an additional 73,238 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Agile Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares in the last quarter. 43.73% of the stock is owned by institutional investors and hedge funds.

Agile Therapeutics stock opened at $1.44 on Tuesday. The business has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.32. Agile Therapeutics has a 12 month low of $0.32 and a 12 month high of $1.70.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Further Reading: What is a good rate of return for a mutual fund?

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Oil States International  Set to Announce Quarterly Earnings on Thursday
Oil States International Set to Announce Quarterly Earnings on Thursday
Synchrony Financial  Releases  Earnings Results, Beats Expectations By $0.10 EPS
Synchrony Financial Releases Earnings Results, Beats Expectations By $0.10 EPS
ADVA Optical Networking  to Release Quarterly Earnings on Thursday
ADVA Optical Networking to Release Quarterly Earnings on Thursday
Endurance Wealth Management Inc. Acquires 49 Shares of NextEra Energy Inc
Endurance Wealth Management Inc. Acquires 49 Shares of NextEra Energy Inc
Endurance Wealth Management Inc. Decreases Stock Position in iShares MSCI Emerging Markets ETF
Endurance Wealth Management Inc. Decreases Stock Position in iShares MSCI Emerging Markets ETF
Endurance Wealth Management Inc. Has $1.26 Million Holdings in iShares Core S&P Mid-Cap ETF
Endurance Wealth Management Inc. Has $1.26 Million Holdings in iShares Core S&P Mid-Cap ETF


© 2006-2019 Ticker Report